Wall Street Breakfast Viking weight loss pill sees positive early data
Nov 4, 2024
Viking Therapeutics' experimental obesity pill, VK2735, shows promising results, with patients losing an average of 8.2% of body weight. Peloton receives a notable double upgrade, hinting at a brighter future. Meanwhile, regulators have blocked the Talen-Amazon power deal amid shifting market dynamics. Marriott's outlook dims due to sluggish demand in the Chinese markets, reflecting broader economic uncertainties.
AI Snips
Chapters
Transcript
Episode notes
Viking Therapeutics' Obesity Pill Shows Promise
- Viking Therapeutics' experimental obesity pill, VK2735, shows promising results in early trials.
- Patients on 100mg doses lost 8.2% of their body weight after 28 days, with side effects similar to other obesity drugs.
Peloton Upgrade
- Bank of America upgraded Peloton Interactive to a buy from underperform, predicting potential EBITDA exceeding $300 million this year.
- They cite potential operating expense cuts, higher hardware margins, and subscription price increases under new leadership.
Marriott Lowers Outlook
- Marriott lowered its full-year 2024 outlook due to ongoing weakness in the Chinese market.
- They now expect lower profits and gross fee revenues than previously anticipated.